Key Highlights
- Shares of Travere Therapeutics (TVTX) soared 44% following FDA’s approval of FILSPARI for treating FSGS
- FILSPARI represents the inaugural FDA-sanctioned therapy for focal segmental glomerulosclerosis
- The treatment received clearance for adults and pediatric patients 8 years and older who don’t present with nephrotic syndrome
- Over 30,000 U.S. patients could potentially benefit from this therapy
- Investment firm Guggenheim increased its TVTX price target to $54, up from $49, while reaffirming a Buy recommendation
Shares of Travere Therapeutics (TVTX) experienced a remarkable 44% surge on Tuesday following the U.S. Food and Drug Administration’s clearance of FILSPARI (sparsentan) for treating focal segmental glomerulosclerosis, a rare kidney condition that previously had no sanctioned therapeutic options.
Travere Therapeutics, Inc., TVTX
The regulatory green light encompasses adult patients as well as pediatric cases starting from age 8 who are diagnosed with FSGS but don’t exhibit nephrotic syndrome. This milestone establishes FILSPARI as the pioneering FDA-sanctioned medication specifically for FSGS.
The approval represents FILSPARI’s second indication for rare kidney disorders, complementing its existing authorization for IgA nephropathy treatment.
According to Travere’s projections, the eligible patient population in the United States exceeds 30,000 individuals with FSGS who satisfy the treatment criteriaâspecifically, those not presenting all three simultaneous indicators of nephrotic syndrome.
Clinical Trial Results
The regulatory decision stemmed from data generated in the Phase 3 DUPLEX Study, characterized as the most extensive interventional clinical trial conducted in FSGS to date.
Participants receiving FILSPARI demonstrated a 46% decrease in proteinuria measured from baseline through Week 108. By comparison, patients treated with maximum-dose irbesartan, the control medication, achieved a 30% reduction.
Among the subset of patients specifically without nephrotic syndrome, FILSPARI produced a 48% proteinuria reduction compared to 27% for those on irbesartan.
Additionally, FILSPARI-treated participants in this subgroup exhibited eGFR benefits, showing a treatment advantage of 1.1 mL/min/1.73 m² measured at Week 108.
The medication demonstrated a safety profile consistent with irbesartan in both adult and pediatric populationsâa favorable outcome that should support commercial adoption.
Wall Street’s Response
Following the announcement, Guggenheim’s analyst Vamil Divan elevated his price objective for TVTX from $49 to $54 while maintaining a Buy recommendation.
Divan characterized the final product label as exceeding expectations, highlighting that the approved patient population proved broader than market consensus had anticipated.
Notably, the label encompasses both primary and secondary FSGS presentationsâextending beyond just the primary and genetic variants that Wall Street analysts and company management had been factoring into their models.
This expanded coverage creates a substantially larger commercial opportunity than many investors had previously incorporated into valuations.
TipRanks reports an additional analyst Buy rating with a $47 price objective on the stock, while assigning a Buy rating to the technical sentiment indicator.
Following Tuesday’s rally, TVTX’s market capitalization stands at roughly $2.67 billion.
The FDA’s approval announcement came on April 13, 2026, with the stock’s dramatic reaction occurring during Tuesday’s market hours.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
